Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
Journal Information
Full Title: Cancer Manag Res
Abbreviation: Cancer Manag Res
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Disclosure Yuntae Kim reports no conflicts of interest in this work. Shun Yamamoto reports having received honoraria from ONO and BMS, MSD. Ken Kato reports having received consulting fees from BMS and MSD, BeiGene, Roche, AstraZeneca, Bayer, honoraria from ONO and BMS, Taiho, and research funding from ONO and BMS, MSD, BeiGene, Chugai, Shionogi, AstraZeneca, BAYER, all of which is unrelated to the submitted work. The authors report no other conflicts of interest in this work."
Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025